BG107752A - Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти - Google Patents

Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти Download PDF

Info

Publication number
BG107752A
BG107752A BG107752A BG10775203A BG107752A BG 107752 A BG107752 A BG 107752A BG 107752 A BG107752 A BG 107752A BG 10775203 A BG10775203 A BG 10775203A BG 107752 A BG107752 A BG 107752A
Authority
BG
Bulgaria
Prior art keywords
salt
isothiazole
ray diffraction
bromo
ureido
Prior art date
Application number
BG107752A
Other languages
Bulgarian (bg)
English (en)
Inventor
Thomas G. Gant
Glenn R. Williams
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG107752A publication Critical patent/BG107752A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG107752A 2000-11-28 2003-04-22 Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти BG107752A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28
PCT/IB2001/002193 WO2002044158A1 (en) 2000-11-28 2001-11-19 Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents

Publications (1)

Publication Number Publication Date
BG107752A true BG107752A (bg) 2004-01-30

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107752A BG107752A (bg) 2000-11-28 2003-04-22 Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти

Country Status (50)

Country Link
US (1) US6831091B2 (pt)
EP (1) EP1337521B1 (pt)
JP (2) JP2004514714A (pt)
KR (2) KR20030059275A (pt)
CN (1) CN1231474C (pt)
AP (1) AP2001002358A0 (pt)
AR (1) AR031512A1 (pt)
AT (1) ATE340786T1 (pt)
AU (2) AU1420402A (pt)
BG (1) BG107752A (pt)
BR (1) BR0115621A (pt)
CA (1) CA2430065C (pt)
CR (1) CR6963A (pt)
CY (1) CY1106240T1 (pt)
CZ (1) CZ20031315A3 (pt)
DE (1) DE60123461T2 (pt)
DK (1) DK1337521T3 (pt)
DO (1) DOP2001000288A (pt)
EA (1) EA005859B1 (pt)
EC (1) ECSP034628A (pt)
EE (1) EE200300247A (pt)
ES (1) ES2271086T3 (pt)
GE (1) GEP20053652B (pt)
GT (1) GT200100237A (pt)
HK (1) HK1059085A1 (pt)
HN (1) HN2001000268A (pt)
HR (1) HRP20030408A2 (pt)
HU (1) HUP0302553A3 (pt)
IL (1) IL155371A0 (pt)
IS (1) IS6788A (pt)
MA (1) MA26960A1 (pt)
MX (1) MXPA03004714A (pt)
MY (1) MY136686A (pt)
NO (1) NO325187B1 (pt)
NZ (1) NZ525788A (pt)
OA (1) OA12532A (pt)
PA (1) PA8533801A1 (pt)
PE (1) PE20020591A1 (pt)
PL (1) PL362079A1 (pt)
PT (1) PT1337521E (pt)
SI (1) SI1337521T1 (pt)
SK (1) SK5862003A3 (pt)
SV (1) SV2002000748A (pt)
TN (1) TNSN01167A1 (pt)
TW (1) TWI287542B (pt)
UA (1) UA74221C2 (pt)
UY (1) UY27039A1 (pt)
WO (1) WO2002044158A1 (pt)
YU (1) YU36403A (pt)
ZA (1) ZA200303341B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
JP4511352B2 (ja) * 2002-07-25 2010-07-28 ファイザー・インク 抗癌薬として有用なイソチアゾール誘導体
CN1681495B (zh) * 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
AU2004287416C1 (en) * 2003-10-27 2010-09-09 Merck Sharp & Dohme Corp. CCR-2 antagonist salt
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
PL2044043T5 (pl) 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
JP2013538191A (ja) 2010-07-23 2013-10-10 トラスティーズ オブ ボストン ユニバーシティ 病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗ＤＥｓｕｐＲ阻害剤
BR112015021334B1 (pt) * 2013-03-14 2020-04-07 Panoptica Inc formulação ocular tópica em suspenão e uso da mesma para tratamento e/ou melhora de uma doença do segmento posterior do olho
NZ767710A (en) * 2014-09-17 2023-09-29 Panoptica Inc Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
EA200300424A1 (ru) 2003-10-30
CA2430065A1 (en) 2002-06-06
TNSN01167A1 (fr) 2005-11-10
HUP0302553A2 (hu) 2003-11-28
BR0115621A (pt) 2003-09-02
DE60123461D1 (de) 2006-11-09
JP4971946B2 (ja) 2012-07-11
US6831091B2 (en) 2004-12-14
AU2002214204B2 (en) 2007-05-24
SI1337521T1 (sl) 2006-12-31
GEP20053652B (en) 2005-11-10
EE200300247A (et) 2003-10-15
PA8533801A1 (es) 2002-10-31
OA12532A (en) 2006-06-02
ECSP034628A (es) 2003-07-25
AP2001002358A0 (en) 2001-12-31
NO325187B1 (no) 2008-02-11
CA2430065C (en) 2008-05-20
ES2271086T3 (es) 2007-04-16
US20020151573A1 (en) 2002-10-17
ATE340786T1 (de) 2006-10-15
IS6788A (is) 2003-04-14
CR6963A (es) 2003-11-25
CZ20031315A3 (cs) 2004-04-14
GT200100237A (es) 2002-07-03
MA26960A1 (fr) 2004-12-20
EP1337521A1 (en) 2003-08-27
KR20050116401A (ko) 2005-12-12
CN1476439A (zh) 2004-02-18
SK5862003A3 (en) 2004-05-04
TWI287542B (en) 2007-10-01
EP1337521B1 (en) 2006-09-27
UY27039A1 (es) 2002-07-31
JP2008056692A (ja) 2008-03-13
KR20030059275A (ko) 2003-07-07
ZA200303341B (en) 2004-04-30
WO2002044158A1 (en) 2002-06-06
PL362079A1 (en) 2004-10-18
DK1337521T3 (da) 2007-01-29
PE20020591A1 (es) 2002-07-06
NO20032388L (no) 2003-07-18
NZ525788A (en) 2004-11-26
JP2004514714A (ja) 2004-05-20
HK1059085A1 (en) 2004-06-18
NO20032388D0 (no) 2003-05-27
AU1420402A (en) 2002-06-11
EA005859B1 (ru) 2005-06-30
IL155371A0 (en) 2003-11-23
HUP0302553A3 (en) 2009-03-30
MY136686A (en) 2008-11-28
HN2001000268A (es) 2002-01-30
HRP20030408A2 (en) 2003-08-31
UA74221C2 (uk) 2005-11-15
CY1106240T1 (el) 2011-06-08
MXPA03004714A (es) 2003-08-19
SV2002000748A (es) 2002-12-02
YU36403A (sh) 2006-08-17
CN1231474C (zh) 2005-12-14
PT1337521E (pt) 2006-12-29
DE60123461T2 (de) 2007-02-15
DOP2001000288A (es) 2002-12-15
AR031512A1 (es) 2003-09-24

Similar Documents

Publication Publication Date Title
BG107752A (bg) Соли на изотиазол-4-карбоксамид и тяхното приложение като антихиперпролиферативни агенти
EP1187826B1 (en) Heterocyclic derivatives useful as anticancer agents
AU2002214204A1 (en) Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
JP6231556B2 (ja) Ｎ−［５−（３，５−ジフルオロ−ベンジル）−１ｈ−インダゾール−３−イル］−４−（４−メチル−ピペラジン−１−イル）−２−（テトラヒドロ−ピラン−４−イルアミノ）−ベンズアミドの調製方法
TWI620748B (zh) 氨基噻唑化合物及其用途
BG65180B1 (bg) Тиенопиридинови производни, полезни като противоракови средства
JP2017128612A (ja) Ａｒｒｙ−３８０の多形体、選択的ｅｒｂｂ２（ｈｅｒ２）阻害剤、およびそれらを含有する薬学的組成物
UA75482C2 (en) Salts of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methylpyridine-3-yloxy)phenylamino]quinozaline -6-yl}alyl)acetamide, a method for the preparation and use thereof for the treatment of cancer
UA60363C2 (uk) Безводні і моногідратні форми n-(3-етинілфеніламіно)-6,7-біс(2-метоксіетокси)-4- хіназолінаміну мезилату
PT1636215E (pt) Furazanobenzimidazoles
JP2020523348A (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
WO2024008129A1 (zh) 作为kat6抑制剂的化合物
TW202220982A (zh) 噻唑化合物作為蛋白質激酶抑制劑
CN100471841C (zh) (2-甲酰胺基)(3-氨基)噻吩化合物
EP3740208A1 (en) Compounds for treating rac-gtpase mediated disorder
WO2014082230A1 (zh) 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用